This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignee: Novo Nordisk A/s. Active years: 2018-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2023
Title: Claudia Ulrich Hjoerringgaard: Innovator in Diabetes Treatment
Introduction
Claudia Ulrich Hjoerringgaard is a prominent inventor based in Glostrup, Denmark. She has made significant contributions to the field of diabetes treatment through her innovative research and development of pharmaceutical compounds. With a total of 3 patents, her work focuses on improving the lives of individuals affected by diabetes and related medical conditions.
Latest Patents
Hjoerringgaard's latest patents include groundbreaking inventions such as "Bifunctional compounds comprising insulin peptides and EGF(A) peptides." This invention relates to novel covalently linked bi-functional fusion proteins that combine insulin and EGF(A) analogues or derivatives. These compounds have potential pharmaceutical applications for treating or preventing medical conditions associated with diabetes and dyslipidaemia. Another significant patent is "Insulin derivatives and the medical uses hereof," which focuses on novel acylated derivatives of human insulin analogues. This invention also provides pharmaceutical compositions for the treatment or prevention of diabetes-related medical conditions.
Career Highlights
Claudia Ulrich Hjoerringgaard is currently associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. Her work at Novo Nordisk has allowed her to contribute to the development of innovative therapies that address critical health issues related to diabetes.
Collaborations
Throughout her career, Hjoerringgaard has collaborated with esteemed colleagues such as Peter Madsen and Susanne Hostrup. These collaborations have fostered a productive environment for research and innovation in the field of diabetes treatment.
Conclusion
Claudia Ulrich Hjoerringgaard is a key figure in the advancement of diabetes therapies, with her patents reflecting her commitment to improving patient outcomes. Her work continues to inspire innovation in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile